BioNexus Gene Lab Corp risk profile
59 Elevated one input has moved against it
Measured 1 September 2026 from BGLC's filed statements. Recomputed nightly.
59 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 84 | Acute | Volatile | One-year price volatility — 74.1% |
| Operating pressure | 74 | Stretched | Easing | Operating-margin drift — -37.3 percentage points |
| Cash conversion | 100 | Acute | Stable | Capital spending against operating cash — -0.02x |
| Leverage and coverage | 35 | Normal | Stable | Interest cover — -143.12x |
| Competitive position | 42 | Elevated | Stable | Revenue-growth gap against peers — -16.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Basic Materials companies with a risk reading
BHP Group Ltd 22Linde Plc. 36Industria De Diseno Textil SA 28Southern Copper Corporation 15Rio Tinto Group 42Rio Tinto plc 42Newmont Corp 12Freeport-McMoRan Inc 38Agnico Eagle Mines Ltd 9Glencore plc 61Sherwin-Williams Company 45Ecolab Inc 39
Financials, valuation and price history for BioNexus Gene Lab Corp